The Stem Cell Revolution.


Like the IT-revolution has changed our way to handle data and communication, stem cells will revolutionize almost any aspect of medicine including treatments for cancer, inflammatory and autoimmune disorders as well as regeneration of new tissues.

See our latest film about our progress in our diabetes research.

What We Do

Ongoing clinical trial with ProTrans

NextCell Pharma is conducting a clinical trial with ProTrans for treatment of patients with type 1-diabetes being 18-40 years who received their diagnosis no later than 2 years ago and still have some insulin production. This is a two-part phase I/II trial design assessing the safety and efficacy of the study drug. In the first part, a dose-escalation with three patients in 3 dose cohorts is used to evaluate the safety. The second part of the trial is started after all patients in the first part have been to the 1-month follow-up visit. The second part includes 15 patients that are randomized to active treatment or placebo (2:1 ratio), both patients and investigators are blinded.

The sponsor of the study is NextCell and the principal investigator is Professor Per-Ola Carlsson, working at Uppsala University and the Uppsala Academic Hospital. The study is conducted at the KTA Phase I unit located at Karolinska University Hospital in Huddinge. Professor Ulf Smith MD, PhD, Professor Anders Fasth, MD, PhD, and Professor Åke Lernmark PhD, together form the Data Safety Monitoring Board with Ulf Smith as its chairman.

Update on the clinical trial: Now recruiting patients into phase-II of the trial!

Achieved milestones


First two patients have been treated in the phase-II part of the clinical trial


Approval by the Data and Safety Monitoring board to proceed with the second part of the trial


All three patients in the high-dose-cohort treated (nine patients have been treated in total)


Approval by the Data and Safety Monitoring board to proceed with the high-dose cohort


All three patients in the medium-dose-cohort treated (six patients have been treated in total)


Approval by the Data and Safety Monitoring Board to proceed with the medium-dose cohort


All three patients in the low-dose-cohort treated



First patient treated


First patient included


First batch of ProTrans clinical grade released for usage in the clinical trial


Initiation meeting at Karolinska Trial Alliance, Huddinge


Karolinska Center for Cell Therapy approves that the trial will be conducted at Karolinska


Permission granted by the Medicinal Product Agency


Permission granted by the Ethics Committee


Clinical trial application submitted


Stem Cells Offer Unlimited Applications


Hematopoietic Stem Cells


Mesenchymal Stem Cells

Stem Cells and Immunology in Synergy

NextCell Pharma is an innovative Biotech growing out of the need for Advanced Therapy Medicinal Products for Autoimmune Disease and Transplantation. Cellaviva, the first Swedish family saving stem cell bank, with its expertise in umbilical cord stem cells and Diamyd Medical with its interests and investments within autoimmune diseases made a natural partnership for creating NextCell Pharma. A plan for testing NextCell Pharma’s first product ProTrans in the clinic is in place.

Type 1 Diabetes

Type 1 diabetes is an autoimmune condition in which the immune system is attacking the insulin producing cells in the pancreas. The causes of this autoimmune reaction is not known and is not linked to modifiable lifestyle factors. There is no cure and it cannot be prevented. Only 5% of people with diabetes have this form of the disease which is usually diagnosed in children and young adults. Between 20-40 million are living with type 1 diabetes worldwide.

ProTrans will be given to patients directly after diagnosis. It is the immunomodulating effect of the stem cells in ProTrans is given in an attempt to protect the insulin producing cells and to modulate the immune system. The effect might be transient, resulting in an longer honeymoon phase or reduced need of insulin, but the goal is to reprogram the immune system to accept the body’s own insulin producing cells.

What We Do

ProTrans™ — For Autoimmune & Inflammatory Diseases and Transplants

We are developing ProTrans™ for therapeutic immunomodulation of autoimmune and inflammatory diseases including for transplantation applications. Mesenchymal stem cells have proven to have immunomodulatory effects.

What We Do

An “Off-The-Shelf” Product

ProTrans is an “off-the-shelf” product based on Wharton’s Jelly derived Mesenchymal Stem Cells (WJMSC). ProTrans is an Advanced Therapy Investigational Medicinal Product (ATIMP).

Renal Transplant

Kidney transplantation has become standard therapy for eligible patients with end stage renal disease. The number of transplants has increased rapidly over the last two decades. However, the demand for organs has increased even more. Deceased donor kidneys are the origin of the majority of all transplants, 50 000 annually. The criteria for an acceptable kidney has been modified to include so called marginal kidneys and donors. Transplants with marginal kidneys have a higher risk of rejection.

The rationale is to give ProTrans to the patient at the time of transplantation in order to protect the kidney, empowering the engraftment. High risk patients would receive ProTrans in addition to conventional immunosuppression with the purpose to foster the engraftment of the marginal kidney.

Two Business Areas based on the same technology

NextCell Pharma develops novel treatments with stem cells from the umbilical cord. In umbilical cord and umbilical cord tissue there are young and viable stem cells that can be collected without any intervention.

NextCell Pharma develops the drug candidate ProTrans™, a stem cell product based on mesenchymal stem cells from umbilical cord tissue with regenerative and immunosuppressive activity.

Cellaviva™ is the brand name of our service for stem cell banking. We offer prospective parents a service for saving their child’s stem cells for the family and the child’s  future medical need.


Cellaviva will always be the first Swedish family cell bank for stem cells and is the only biobank with approval from Swedish authorities. Cellaviva and NextCell Pharma have a high scientific profile with a strong network with academic researchers.   Family stem cell banking and cord blood banking is a proven business model. Expectant parents all over the world have been offered to store stem cells from their newborn children for more than two decades. Today 200 companies have stored stem cells from more than 4 million children, globally.



Karolinska Institutet Science Park
Hälsovägen 7, 141 57 Huddinge
+46 (0)8 735 55 95